Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 4—April 2007
Dispatch

Endpoints for Lymphatic Filariasis Programs

Caroline A. Grady*, Madsen Beau de Rochars†, Abdel N. Direny†, Jean Nicolas Orelus†, Joyanna Wendt*, Jeanne Radday*, Els Mathieu*, Jacquelin M. Roberts*, Thomas G. Streit‡, David G. Addiss*, and Patrick J. Lammie*Comments to Author 
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hopital Ste. Croix, Leogane, Haiti; ‡University of Notre Dame, Notre Dame, Indiana, USA;

Main Article

Table

Drug coverage for Leogane Commune, Haiti

2000 2001 2002 2003 2004
No. treated* 74,000 55,000 94,000 102,000 122,000
Reported coverage† 69% 50% 84% 89% 104%
Surveyed coverage‡ 71% NA 79% NA NA
Adverse events§ 23% 16% 9% 8% 3%

*Based on tally counts from distribution posts.
†Using 108,000 as the total population of Leogane determined by cluster survey in 2000, adjusted for annual population growth.
International Data Base (IDB): available from http://www.census.gov/ipc/www/idbprint.html
‡Published data (7,8)
§Based on the number of persons who reported to distribution posts with reportts adverse events as a percentage of the reported coverage. See reference (9) for a more detailed discussion of adverse events associated with the first round of mass drug administration..

Main Article

References
  1. Ottesen  EA, Duke  BO, Karam  M, Behbehani  K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ. 1997;75:491–503.PubMedGoogle Scholar
  2. World Health Organization. Global programme to eliminate lymphatic filariasis: progress report on mass drug administrations in 2005. Wkly Epidemiol Rec. 2006;81:221–32.PubMedGoogle Scholar
  3. Ramzy  RMR, El Setouhy  M, Helmy  H, Ahmed  ES, Abd Elaziz  KM, Farid  HA, Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet. 2006;367:992–9. DOIPubMedGoogle Scholar
  4. Mohammed  KA, Molyneux  DH, Albonico  M, Rio  F. Progress toward eliminating lymphatic filariasis in Zanzibar: a model programme. Trends Parasitol. 2006;22:340–4. DOIPubMedGoogle Scholar
  5. de Rochars  MB, Kanjilal  S, Direny  AN, Radday  J, Lafontant  JG, Mathieu  E, The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration. Am J Trop Med Hyg. 2005;73:888–94.PubMedGoogle Scholar
  6. Goodman  DS, Orelus  JN, Roberts  JM, Lammie  PJ, Streit  T. PCR and mosquito dissection as tools to monitor filarial infection following mass treatment. Filaria Journal [serial online]. 2003 July; 2(11): [about 9 p.]. Available from http://www.filariajournal.com/content/2/1/11.
  7. Mathieu  E, Deming  M, Lammie  PJ, McLaughlin  SI, Beach  MJ, Deodat  DJ, Comparison of methods for estimating drug coverage for filariasis elimination, Leogane Commune, Haiti. [PMID: 15307410]. Trans R Soc Trop Med Hyg. 2003;97:501–5. DOIPubMedGoogle Scholar
  8. Mathieu  E, Direny  A, Beau de Rochars  M, Streit  T, Addiss  DG, Lammie  PJ. Participation in three consecutive mass drug administrations in Leogane, Haiti. Trop Med Int Health. 2006;11:862–8. DOIPubMedGoogle Scholar
  9. McLaughlin  SI, Radday  J, Michel  MC, Addiss  DG, Beach  MJ, Lammie  PJ, Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. Am J Trop Med Hyg. 2003;68:568–73.PubMedGoogle Scholar
  10. Stolk  WA, Swaminathan  S, van Oortmarssen  GJ, Das  PK, Habbema  JD. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: A simulation study. J Infect Dis. 2003;188:1371–81. DOIPubMedGoogle Scholar
  11. Michael  E, Malecela-Lazaro  MN, Simonsen  PE, Pedersen  EM, Barker  G, Kumar  A, Mathematical modeling and the control of lymphatic filariasis. Lancet Infect Dis. 2004;4:223–33. DOIPubMedGoogle Scholar
  12. Lammie  P, Weil  G, Noordin  R, Kaliraj  P, Steel  C, Goodman  D, Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis - a multicenter trial. Filaria Journal [serial online]. 2004;3(9). Available from http://www.filariajournal.com/content/3/1/9.
  13. Bockarie  MJ, Tisch  DJ, Kastens  W, Alexander  ND, Dimber  Z, Bockarie  F, Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med. 2002;347:1841–8. DOIPubMedGoogle Scholar
  14. Ramaiah  KD, Das  PK, Vanamail  P, Pani  SP. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes. Trop Med Int Health. 2003;8:1082–92. DOIPubMedGoogle Scholar
  15. Richards  FO Jr, Pam  DD, Kal  A, Gerlong  GY, Onyeka  J, Sambo  Y, Significant decrease in the prevalence of Wuchereria bancrofti infection in anopheline mosquitoes following the addition of albendazole to annual ivermectin-based, mass treatments in Nigeria. Ann Trop Med Parasitol. 2005;99:155–64. DOIPubMedGoogle Scholar

Main Article

Page created: June 28, 2010
Page updated: June 28, 2010
Page reviewed: June 28, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external